{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:38:31Z","timestamp":1763552311776},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ando.2024.05.019","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T02:19:17Z","timestamp":1718245157000},"page":"190-194","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Primary disease of adipose tissue: When to think about and how to evaluate it in clinical practice?"],"prefix":"10.1016","volume":"85","author":[{"given":"Camille","family":"Vatier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Vigouroux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e9na","family":"Mosbah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2024.05.019_bib0195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/db19-0447","article-title":"Clinical and molecular prevalence of lipodystrophy in an unascertained large clinical care cohort","volume":"69","author":"Gonzaga-Jauregui","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.05.019_bib0200","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ejendo\/lvad169","article-title":"Patients\u2019 perspective on the medical pathway from first symptoms to diagnosis in genetic lipodystrophy","volume":"190","author":"Mosbah","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.05.019_bib0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ando.2019.10.003","article-title":"Lipodystrophic syndromes: from diagnosis to treatment","volume":"81","author":"Sollier","year":"2020","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2024.05.019_bib0210","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.019_bib0215","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ando.2024.05.019_bib0220","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13023-022-02308-7","article-title":"Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins)","volume":"17","author":"Mosbah","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ando.2024.05.019_bib0225","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/19491034.2018.1509659","article-title":"Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects","volume":"9","author":"Gambineri","year":"2018","journal-title":"Nucleus"},{"key":"10.1016\/j.ando.2024.05.019_bib0230","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.diabet.2018.09.006","article-title":"Cardiometabolic assessment of lamin A\/C gene mutation carriers: a phenotype-genotype correlation","volume":"45","author":"Kwapich","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ando.2024.05.019_bib0235","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1530\/EJE-21-0282","article-title":"A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies","volume":"185","author":"Treiber","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.05.019_bib0240","doi-asserted-by":"crossref","DOI":"10.1093\/ejendo\/lvad023","article-title":"Perinatal, metabolic, and reproductive features in PPARG-related lipodystrophy","volume":"188","author":"Gosseaume","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.05.019_bib0245","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/j.1572-0241.2005.00234.x","article-title":"Hepatic steatosis in Dunnigan-type familial partial lipodystrophy","volume":"100","author":"L\u00fcdtke","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ando.2024.05.019_bib0250","first-page":"261","article-title":"Adipokines. Leptine, adiponectine, syndromes lipodystrophiques et d\u2019insulino-r\u00e9sistance s\u00e9v\u00e8re [Leptin, adiponectin, lipodystrophic and severe insulin resistance syndromes]","volume":"78","author":"Vatier","year":"2020","journal-title":"Ann Biol Clin (Paris)"},{"key":"10.1016\/j.ando.2024.05.019_bib0255","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1210\/clinem\/dgaa137","article-title":"Diagnostic value of anthropometric measurements for familial partial lipodystrophy, Dunnigan variety","volume":"105","author":"Vasandani","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.019_bib0260","doi-asserted-by":"crossref","first-page":"428","DOI":"10.5152\/dir.2017.17019","article-title":"Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy","volume":"23","author":"Altay","year":"2017","journal-title":"Diagn Interv Radiol"},{"key":"10.1016\/j.ando.2024.05.019_bib0265","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1210\/jc.2016-1005","article-title":"Natural history of congenital generalized lipodystrophy: a nationwide study from Turkey","volume":"101","author":"Akinci","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.019_bib0270","doi-asserted-by":"crossref","DOI":"10.1038\/ejhg.2016.53","article-title":"Clinical utility gene card for: congenital generalized lipodystrophy","volume":"24","author":"J\u00e9ru","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.ando.2024.05.019_bib0275","doi-asserted-by":"crossref","first-page":"103819","DOI":"10.1016\/j.ejmg.2019.103819","article-title":"Congenital generalized lipodystrophy: the evaluation of clinical follow-up findings in a series of five patients with type 1 and two patients with type 4","volume":"63","author":"G\u00fcne\u015f","year":"2020","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.ando.2024.05.019_bib0280","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1210\/jc.2003-030855","article-title":"Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy","volume":"88","author":"Agarwal","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.019_bib0285","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00431-019-03521-6","article-title":"Neonatal cardiac hypertrophy: the role of hyperinsulinism-a review of literature","volume":"179","author":"Paauw","year":"2020","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.ando.2024.05.019_bib0290","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1651-2227.1996.tb14264.x","article-title":"Cardiac findings in generalized lipodystrophy","volume":"413","author":"Bj\u00f8rnstad","year":"1996","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.ando.2024.05.019_bib0295","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.amjcard.2013.05.036","article-title":"Cardiac steatosis and left ventricular hypertrophy in patients with generalized lipodystrophy as determined by magnetic resonance spectroscopy and imaging","volume":"112","author":"Nelson","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ando.2024.05.019_bib0300","first-page":"539","article-title":"Endocrinol Metab Clin North Am","volume":"46","author":"Lightbourne","year":"2017","journal-title":"Genetics of lipodystrophy"},{"key":"10.1016\/j.ando.2024.05.019_bib0305","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/s41588-023-01535-3","article-title":"Loss of phospholipase PLAAT3 causes a mixed lipodystrophic and neurological syndrome due to impaired PPAR\u03b3 signaling","volume":"55","author":"Schuermans","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.ando.2024.05.019_bib0310","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3390\/jcm10071435","article-title":"Celia's encephalopathy (BSCL2-gene-related): current understanding","volume":"10","author":"S\u00e1nchez-Iglesias","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ando.2024.05.019_bib0315","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00256-016-2457-9","article-title":"Bone imaging findings in genetic and acquired lipodystrophic syndromes: an imaging study of 24 cases","volume":"45","author":"Teboul-Cor\u00e9","year":"2016","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.ando.2024.05.019_bib0320","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/s41598-023-27987-5","article-title":"Identifying congenital generalized lipodystrophy using deep learning-DEEPLIPO","volume":"13","author":"da Cunha Olegario","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ando.2024.05.019_bib0325","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00125-022-05666-w","article-title":"When therapeutic drugs lead to diabetes","volume":"65","author":"F\u00e8ve","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2024.05.019_bib0330","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","article-title":"Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature","volume":"82","author":"Misra","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ando.2024.05.019_bib0335","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc18-2535","article-title":"Acquired generalized lipodystrophy: a new cause of anti-PD-1 Immune-related diabetes","volume":"42","author":"Jehl","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2024.05.019_bib0340","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2337\/db21-1086","article-title":"Characterization and clinical association of autoantibodies against Perilipin 1 in patients with acquired generalized lipodystrophy","volume":"72","author":"Corvillo","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.05.019_bib0345","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2337\/db21-1172","article-title":"Autoantibodies to Perilipin-1 define a subset of acquired generalized lipodystrophy","volume":"72","author":"Mandel-Brehm","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.05.019_bib0350","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2024.05.019_bib0355","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41572-020-0181-1","article-title":"HIV and antiretroviral therapy-related fat alterations","volume":"6","author":"Koethe","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ando.2024.05.019_bib0360","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-014-0282-9","article-title":"Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events","volume":"74","author":"Fardet","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ando.2024.05.019_bib0365","article-title":"Clinical characteristics of patients with acquired partial lipodystrophy: a multicenter retrospective study","author":"Magno","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.019_bib0370","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/brain\/111.5.1157","article-title":"Neuropathy in multiple symmetric lipomatosis. Madelung's disease","volume":"111","author":"Pollock","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.ando.2024.05.019_bib0375","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2147\/DMSO.S363836","article-title":"Madelung's Disease: analysis of clinical characteristics, fatty mass distribution, comorbidities and treatment of 54 patients in China","volume":"15","author":"Li","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.ando.2024.05.019_bib0380","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jacl.2018.07.009","article-title":"I.\u00a0MFN2-associated lipomatosis: clinical spectrum and impact on adipose tissue","volume":"12","author":"Capel","year":"2018","journal-title":"J Clin Lipidol"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000342662400074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000342662400074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T22:30:51Z","timestamp":1723329051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000342662400074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S000342662400074X"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2024.05.019","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary disease of adipose tissue: When to think about and how to evaluate it in clinical practice?","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2024.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}